The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Cidara Therapeutics | Common Stock | 171757107 | 7,846 | 1,508,794 | SH | SOLE | 1,508,794 | 0 | 0 | ||
| CymaBay Therapeutics | Common Stock | 23257D103 | 7,401 | 551,477 | SH | SOLE | 551,477 | 0 | 0 | ||
| Dicerna Pharmaceuticals | Common Stock | 253031108 | 2,737 | 223,457 | SH | SOLE | 223,457 | 0 | 0 | ||
| Egalet | Common Stock | 28226B104 | 1,220 | 2,889,926 | SH | SOLE | 2,889,926 | 0 | 0 | ||
| ESSA Pharma | Common Stock | 29668H104 | 4,122 | 1,084,848 | SH | SOLE | 1,084,848 | 0 | 0 | ||
| FibroGen | Common Stock | 31572Q808 | 8,178 | 130,646 | SH | SOLE | 130,646 | 0 | 0 | ||
| Jounce Therapeutics | Common Stock | 481116101 | 4,060 | 529,965 | SH | SOLE | 529,965 | 0 | 0 | ||
| Kezar Life Sciences | Common Stock | 49372L100 | 11,994 | 693,272 | SH | SOLE | 693,272 | 0 | 0 | ||
| ObsEva | Common Stock | H5861P103 | 15,135 | 999,664 | SH | SOLE | 999,664 | 0 | 0 | ||
| Paratek Pharmaceuticals | Common Stock | 699374302 | 26,524 | 2,600,410 | SH | SOLE | 2,600,410 | 0 | 0 | ||
| Pieris Pharmaceuticals | Common Stock | 720795103 | 3,946 | 778,230 | SH | SOLE | 778,230 | 0 | 0 | ||
| Sienna Biopharmaceuticals | Common Stock | 82622H108 | 11,523 | 758,610 | SH | SOLE | 758,610 | 0 | 0 | ||
| Translate Bio | Common Stock | 89374L104 | 30,836 | 2,437,601 | SH | SOLE | 2,437,601 | 0 | 0 | ||